Grace Therapeutics, Inc.
GRCE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001444192
In the last 90 days, Grace Therapeutics, Inc. insiders filed 4 open-market purchases and 0 sales; 33 institutions reported holding it in 13F filings for Q2 2026, worth $8.74M in total; no superinvestor holds it.
13F holders, Q4 2024
Institutional positions in Grace Therapeutics, Inc. as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 15
- +3 vs. Q3 2024
- Shares held
- 2.09M
- −31.7K (−1.5%) vs. Q3 2024
- Total value
- $7.84M
- +$1.47M (+23.2%) vs. Q3 2024
- New holders
- 4
- 2 more added
- Sold out
- 1
- 3 more reduced
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting GRCE on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 33 | $8.74M |
| Q1 2026 | 34 | $19.7M |
| Q4 2025 | 23 | $15.0M |
| Q3 2025 | 20 | $11.0M |
| Q2 2025 | 20 | $11.3M |
| Q1 2025 | 17 | $9.17M |
| Q4 2024 | 15 | $7.84M |
| Q3 2024 | 12 | $6.36M |
| Q2 2024 | 12 | $6.30M |
| Q1 2024 | 10 | $4.34M |
| Q4 2023 | 9 | $1.65M |
| Q3 2023 | 12 | $1.55M |
| Q2 2023 | 11 | $204.2K |
| Q1 2023 | 12 | $189.6K |
| Q4 2022 | 9 | $24.8K |
| Q3 2022 | 9 | $53.1K |
| Q2 2022 | 10 | $108.2K |
| Q1 2022 | 9 | $183.7K |
| Q4 2021 | 13 | $248.8K |
| Q3 2021 | 14 | $356.5K |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding Grace Therapeutics, Inc.; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| ADAR1 Capital Management, LLC | 773,635 | $2.89M | 0.60% | −185,936−19.4% | Reduced |
| AIGH Capital Management LLC | 521,083 | $1.96M | 0.74% | −120,000−18.7% | Reduced |
| Bank of America Corp | 494,698 | $1.85M | 0.00% | 00.0% | Unchanged |
| Vanguard Group Inc | 225,000 | $857.3K | 0.00% | +225,000 | New |
| Renaissance Technologies LLC | 42,975 | $160.7K | 0.00% | +26,828+166.1% | Added |
| Citadel Advisors LLC | 23,664 | $90.2K | 0.00% | +23,664 | New |
| National Bank of Canada | 2,719 | $10.2K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 1,882 | $7.04K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 1,497 | $5.60K | 0.00% | −1,235−45.2% | Reduced |
| Royal Bank of Canada | 546 | $2.00K | 0.00% | +3+0.6% | Added |
| Activest Wealth Management | 104 | $389 | 0.00% | 00.0% | Unchanged |
| Golden State Wealth Management, LLC | 31 | $116 | 0.00% | +31 | New |
| Federation des caisses Desjardins du Quebec | 28 | $105 | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 17 | $65 | 0.00% | 00.0% | Unchanged |
| SBI Securities Co., Ltd. | 1 | $4 | 0.00% | +1 | New |
| UBS Group AG | 0 | $0 | 0.00% | −28−100.0% | Sold out |